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A method to obtain polyvalent anti-Bitis and polyvalent-anti-Naja antibodies was developed by 
immunizing horses with B. arietans, B. nasicornis, B. rhinoceros, N. melanoleuca and N. mossambica 
crude venoms. Antibody production was followed by the ELISA method during the immunization 
procedure. Once the desired anti-venom antibody titers were attained, horses were bled and the 
immunoglobulins were separated from the sera by (NH4)2SO4 precipitation, cleaved with pepsin and 
filtered through a 30 kDa ultrafiltration membrane. F(ab´)2 fragments were further purified by Q-Fast 
Flow chromatography, concentrated by molecular ultrafiltration and sterilized by filtration through 0.22 
m membranes. The resulting F(ab´)2 preparations were rich in intact L and in pieces of H IgG(T) chains, 
as demonstrated by electrophoresis and Western blot and exhibited high antibody titers, as assayed by 
the ELISA method. In addition, the preparations possess a significant capacity to neutralize the lethality 
of venoms, as estimated by ED50 determination in mouse assay and are free of toxic substances, 
pyrogen and bacterial or fungal contaminations.  
 






A workshop to discuss progress in the standardization 
and control of anti-venoms, organized by the Quality 
Assurance and Safety of Biologicals Unit of WHO, was  
held at the National Institute for Biological Standards and 
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Abbreviations: ELISA, Enzyme-linked immunosorbent assay; 
SDS-PAGE, sodium dodecylsulfate - polyacrylamide gel 
electrophoresis; ED50, half maximum effective dose; LD50, half 
maximum lethal dose. 
(Theakston et al., 2003). Among the several important 
considerations raised by the experts invited from academic 
institutions, anti-venom manufacturers and national 
regulatory authorities from 21 countries, was concern 
regarding the crisis, at that time, of antivenom production 
and supply in sub-Saharan Africa. Unfortunately, snake 
bites and scorpion stings continue to be an important 
public health problem and the crisis in antivenom 
production persists and antivenom remains scarce in 
Mozambique. We decided to address this issue, first by 
adapting current procedures to produce anti-African 
snake venoms. Since B. arietans, B. nasicornis, B. 
rhinoceros, N. melanoleuca and N.  mossambica are the 









1968; U.S. Navy, 1991; Manacas, 1981/1982), their venoms 
were used to immunize horses. We proposed, with a 
support grant from the Brazilian Research Foundation 
(CNPq), to develop at the “Instituto Butantan”, Sao Paulo, 
Brazil, two polyvalent anti-venoms, anti-Bitis (B. arietans, 
B. nasicornis, B. rhinoceros) and anti-Naja (N. melanoleuca 
and N. mossambica) antivenoms. Both antivenoms were 
obtained from hyperimmunized horses; the 
immunoglobulins were obtained by ammonium sulfate 
precipitation and the IgG(T) fraction was submitted to 
cleavage with pepsin and the resulting F(ab´)2 fragments 
were further purified, concentrated, analyzed with respect 
to the presence of antivenom specific antibodies by 
ELISA method. Their efficacy to neutralize the venom 
lethality was evaluated in in vitro - in vivo method using 
mice as animal test and the their potency expressed in 
terms of ED50 as recommended by World Health 
Organization (1981).  Both antivenom preparations were 
submitted to routine quality control procedures. The 
results presented herein show that specific, potent 
polyvalent anti-Bitis and anti-Naja antivenoms could be 
obtained on a large scale by using traditional methodology 
with modifications imposed by the venom diversity. 
Before being supplied for the treatment of snake bites in 
Mozambique, these anti-venoms will be submitted to 
clinical trials under the supervision of physicians the 








Adult horses (400 - 450 kg body mass) maintained in a special 
animal house at the Sao Joaquim Farm, Instituto Butantan, Sao 
Paulo, Brazil, were used to produce IgG(T) antivenoms. The horses 
were vaccinated against the commonest equine infectious 
diseases. Swiss outbred mice (18-20 g) were provided by the 
Instituto Butantan Animal Facilities. These male and female mice 
were included in the protocols routinely used to determine the 
lethality (LD50) of the venoms and the neutralizing potency (ED50) of 
the antivenoms. All animals used in this study were maintained and 
treated under strict ethical conditions, according to the “International 
Animal Welfare Recommendations (Remfry, 1987) and by Committee 
Members, International Society on Toxinology (1992).   
 
 
Antigen preparation and analysis 
 
The B. arietans, B.  nasicornis, B. rhinoceros, N. melanoleuca and 
N. mossambica venoms were purchased from Venom Supplies Pty 
Ltd (59 Murray Street, Tanunda, Australia). 
 
 
Immunization and bleeding 
 
Anti-African snake polyclonal antibodies were obtained by 
immunizing horses that were randomly distributed into three groups 
: Group # 1- (Horses No: 476,494, 495, 496, 497, 498 and 499) - B. 
arietans. Group #2 - (Horses No: 508, 509, 510, 511, 512 and 513) 




- B. nasicornis and B. rhinoceros. Group # 3- (Horses No: 501, 502, 
503, 504, 505, 506, 507) - N. melanoleuca and N. mossambica.  
Horses were s.c. injected in the back, successively two weeks apart 
with 2.0 ml of incomplete MMT20, or complete MMT20 adjuvant 
(Marcol-Montanide-Tween -20 adjuvant, Brazil Ltda-Div. SEPPIC/ 
France/Brazil) mixtures, prepared as described by  Herbert (1978) 
or PBS (phosphate saline, pH 7.5) containing 3.0-4.0 mg of venoms. 
Two weeks after the last immunization, when the antibodies against 
the venoms attained an appropriate value, the horses were bled 
and a volume of blood corresponding to one-twelfth of their body 
weight was collected in sterile plastic bags containing anticoagulant. 
Plasma and cells were separated by gravidity sedimentation and 
the cells were re-infused into the corresponding horse through the 
jugular vein. Plasmas from the same horse group were pooled and 
stored at 4°C. Before immunization, blood samples were withdrawn 
by jugular vein puncture and sera stored at -20°C to be used as 
negative controls in the anti-venom antibody determinations. Three 
months after bleeding, boosters with similar doses of venoms in 
PBS were given and blood was collected and processed as 
described. This latter procedure will be repeated for the next two 
years.   
 
 
f(ab´)2 preparation  
 
Serum rich in F(ab’)2 fragments was produced essentially as 
described  by Towbin et al (1979) . A saturated solution of (NH4)2SO4 
was added to the plasma pool obtained from the horses immunized 
with whole African snake venoms until the 29% concentration was 
attained. The precipitates containing mostly immunoglobulins were 
separated by centrifugation, dissolved in distilled water. Pepsin (1.0 
g / 80 g protein) was added, the pH was adjusted to 3.0 - 3.2 with 
40% citric acid and digestion allowed to occur at room temperature 
for 40 min. The pH was adjusted to 4.5 - 4.6 also with 40% citric 
acid and the fibrinogen precipitated by adding 0.01M caprilic acid 
plus 11.3% (NH4)2SO4 and incubated at 55°C for 1h. A saturated 
solution of (NH4)2SO4 was added until attaining a 17.6% final 
concentration. The mixture was centrifuged and precipitates discarded. 
The supernatants were passed on a 30kDa exclusion membrane to 
remove (NH4)2SO4, the resultant F(ab’)2 - rich supernatants were 
concentrated by molecular exclusion on a  Q - Sepharose Fast Flow 
chromatography and sterilized by passing  through a 0.22 µm filter 
membrane. The preparations were analyzed for the presence of 
F(ab’)2 fragments by comparing their relative molecular weight with 
uncleaved IgG(T) on sodium dodecylsulfate - polyacrylamide gel 
electrophoresis (SDS-PAGE) or Western blot analysis, for the 
presence of specific antibodies against snake venom antigens 
using the enzyme-linked immunosorbent assay (ELISA) and for 
their capacity to neutralize venom lethality.  Before release to treat 
envenomed victims, F(ab’)2 fragments are submitted to a quality 
control in order to certify absence of bacterial contamination, 
bacterial lipopolysaccharide and toxic substances. The final products 
are adjusted to contain the desired neutralizing antibody titer in less 
than 10 mg of protein/ml and labeled as Bitis - polyvalent anti-
venom or Naja - polyvalent antivenom. Each ampoule contains 40 
ml of anti-venom. This anti-venom was prepared according to the 
recommendations of the World Health Organization (1981).  
 
 
Characterization of horse antivenom IgG antibodies (SDS-
PAGE and Western blot analyses) 
 
Western blot analysis was carried out, according to the previously 
described method. Laemmili (1970). Crude B. arietans, B. nasicornis, 
B. rhinoceros, N. melanoleuca and N. mossambica-snake venoms 









conditions and resolved in 15% polyacrylamide gel before electro-
blotting onto PVDF (Immobilon P), after treating membranes with 
methanol. The membrane, after treating again with methanol at 
37°C for 15 min, was blocked with blocking buffer (0.01 M PBS, pH 
7.4, with 5% low fat milk) at room temperature for 30 min. After 
washing with wash buffer (blocking buffer containing 0.1% Tween- 
20), the membrane was incubated with 5.0 mg of rabbit anti-horse 
IgG (whole molecule) diluted in the same blocking buffer and 
incubated for 1.0 h at room temperature on a horizontal shaker. The 
membrane was washed with blocking buffer and incubated with 1: 
2000 dilution of peroxidase-conjugated goat anti-rabbit IgG for 1.0 h 
at room temperature. After washing, the membrane was placed in 
peroxidase chromogenic substrate solution (0.1 M citric acid plus 
0.2 M sodium di-phosphate, 5.0 mg of DAB (0.05%) and 3 µl of 
H2O2). The reaction was terminated by washing with distilled water. 
 
 




Production of anti-venom antibodies was initially monitored along 
the immunization schedule by a double-immunodiffusion method 
described by Outchterloni and Nilson (1986). Briefly, 10 l of 
undiluted serum samples were deposited in the central well of a 
0.8% agarose gel, while 10 l of different venom concentrations (10 
-50g) were deposited in peripheral wells and the gels allowed to 
stand overnight in a refrigerator. Developing of precipitin lines by 





Polystyrene ELISA plate (96 wells) was coated with 1.0 g of native 
snake venom in 50 l coating buffer (0.1 M carbonate bi-carbonate, 
pH 9.6) kept overnight at 4°C. The wells were washed once with PBS 
buffer containing 0.05% Tween - 20. The wells were next blocked for 
1.0 h at room temperature with 150 l PBS buffer plus 1.0 % 
gelatin. The wells were again washed thrice with 300 l washing 
buffer. Serial dilutions of horse IgG or F(ab`)2 preparations (1: 1000 
to 320000) in PBS buffer plus 1.0% gelatin buffer containing 0.05% 
Tween - 20  were prepared and 50 l of each were added to 
individual wells and the plates were incubated at 37°C for 45 min. 
The wells were washed five times with the same washing buffer. 
Rabbit peroxidase-conjugated anti-horse IgG (whole molecule), 
diluted (1: 800) in PBS buffer plus 1.0 % gelatin buffer containing 
0.05% Tween - 20 (50 l), was added to each well. The plates were 
incubated for 45 min at 37°C. After five washes with the washing 
buffer, 50 l of substrate buffer (0.1 M citric acid, plus 0.2 M sodium 
di- phosphate, 5.0 ml H2O, 5.0 mg OPD, 5 µl of H2O2) were added 
and incubated at room temperature for 10 - 15 min. The reaction was 
terminated with 50 l of 3N sulfuric acid. Absorbance was recorded at 
492 nm using an ELISA plate reader. IgG from horses collected 
before immunization was always used as a negative control. Wells 
free of venom were used as blanks. The IgG dilution, giving an 
optical density of close to 0.2, was used to calculate the U-ELISA 
per milliliter of undiluted IgG solution. One U-ELISA is defined as 
the smallest amount of antibody giving an O.D. of 0.2 under 
conditions of ELISA assay as described by Almeida et al., (2008). 
 
 
Neutralization of venom lethality by IgY antivenom antibodies  
 
The neutralizing efficacy of horse IgG or F(ab`)2 antivenom antibodies, 
produced along the immunization procedure, was evaluated by 





amounts of horse antivenom antibodies. The mixtures were intra-
peritoneally (i.p) injected into groups of eight Swiss mice (18-20 g). 
The deaths were recorded after 72 h and the death/survival ratio 
recorded (World Health Organization, 1981). The ability of antibodies 
to neutralize the lethal activity of venoms, expressed in terms of 
ED50, is the 50% end point of neutralization, as calculated by the 
Spearman -Karber method Finney (1992). 
Quality control of F(ab`)2 anti-venoms Both Polyvalent Bitis-
antivenom and Polyvalent Naja-antivenom were standardized, 
according to World Health Organization (1981). Quality control tests 
for the presence of bacteria, fungi, toxic substances and pyrogen 





Standardized and certified sterile batches of polyvalent 
anti-Bitis or anti-Naja anti-venoms were produced according 
to the process and flow diagram depicted in Figure 1. 
 
 
Step # 01: Standardization of the antigen mixtures   
 
SDS-PAGE analysis of venoms. B. arietans, B. nasicornis, 
B. rhinocerus, N. melanoleuca and N. mossambica snake 
venoms were submitted to 15% SDS - PAGE under non-
reducing conditions and were resolved into venom 
components with apparent molecular masses ranging 
from 14 to 97 kDa, nine protein bands in B. arietans; (well 
# 2), six in B. nasicornis (well # 3), six in B. rhinoceros 
(well # 4), five in N. melanoleuca (well # 6) and seven in 
N. mossambica (well # 7)). A single protein band with 
apparent molecular mass ranging from 24 - 36 kDa was 
observed only for the B. arietans venom.  
LD50 determination of the venoms. LD50 values found for 
the five Africa snakes venoms used in this study were: B. 
arietans, 0.96µg/mouse; B. nasicornis, 123.67µg/ mouse; 
B. rhinoceros, 95.28 µg/mouse N. melanoleuca, 13.41 
µg/mouse and N. mossambica, 22.40 µg/mouse. 
 
 
Step # 02: Antibody production  
 
With some small individual variations among the horses 
immunized with African snake venoms, anti-venom 
antibodies appear early in the plasmas even during the 
first immunization run, as revealed by a double immune 
diffusion method (data not shown) and quantified by 
ELISA. Figure 2 shows that the antibody titers expressed 
by the number of U-ELISA / ml of serum, varies among 
the individual horses even when immunized with the 
same venom or mixtures of venoms.  
 
 
Step # 03: Refining and standardization of anti-venom 
F(ab´)2 fragments 
 










Separation: Plasma–Blood cells Blood cells: reinjection into 
horses 
Horses: quarantaine    





Immunization    
schedules 
Priming: Four i.p. immunizations two weeks apart  
First booster: Four i.p. immunizations two weeks apart 
Subsequent boosters: Two immunizations two weeks apart  
Pepsin cleavage of IgG(T) 
-Ion exchange chromatography  
Affinity chromatography Potency determination:  





 Clinical trial 
 
 
Figure 1. Process and flow diagram: production of polyvalent Anti-Bitis or Anti-Naja venoms. F(ab´)2  preparation: 




Plasma from horses immunized with African snake 
venoms were digested with pepsin and the correspondent 
F(ab´)2 fragments were prepared according to the 
scheme (Figure 1). The presence of antibodies against 
Bitis or Naja venom antigens was tested by Western blot 
and by ELISA assays. Western blot analysis indicates 
that horse antibodies recognize three protein bands in 
Bitis venoms (Figure 3A) only one in Naja, venoms 
(Figure 3B). On ELISA, the antibody titers, were higher in 
F(ab´)2 fragments as compared with the original IgG 
preparations (Figure 4). When the antibodies titers were 
expressed in terms of U-ELISA /ml of each preparations, 
F(ab´)2 fragments were over 9.0 x 10
5 of U -ELISA, as 
compared with less than 3.0 x 105  for IgG original 
preparation (Figure 5). These preparations also contain 
specific antibodies capable of neutralizing the lethality 
induced by the venoms, as indicated by the ED50 / ml 
values (Table 1).  Western blot analysis demonstrates that 
IgG (T) of both Polyvalent Bitis-anti-venom and Polyvalent 
Naja-anti-venom upon cleavage by pepsin under conditions 
allowing cleavage of the Fc portion of the IgG(T) 
molecule (Nisonoff, 1973) was converted to F(ab´)2 
fragments (Figure 6). 
Step 04: Quality control  
 
The final F(ab´)2  preparations  of both antivenoms were 
vandardized according to the WHO recommendations. 
Quality control tests (bacterial and fungal sterility, 
abnormal toxicity safety), a pyrogen test, as well as 
physic-chemical controls (pH 6.7, total protein content (10 
-12 mg), total nitrogen content) were carried out. One ml 
of these anti-venoms was adjusted in order to equal the 
5DL50 of venom. Forty milliliters of antivenoms were 
packed in 50 ml sterile labeled flasks. Labels included 
basic information on the packed product regarding the 





Snake venom poisoning is a disease process that has 
been successfully treated with polyclonal antibodies. This 
therapeutic tool has been used since pioneering studies 
by Sewall (1887) and Calmette (1894). Conventional anti-
venoms are prepared by immunizing large animals, 











Figure 2. Detection of anti-venoms antibody production in immunized horses by ELISA. Individual horse serum diluted 1:2000 
were added on 96-well pre-coated with 1.0 Polyvalent Horse F(ab`)2  snake  antivenom µg of snake venom as indicated and results 
expressed as U-ELISA \ ml of undiluted serum. Data are presented as mean of triplicates. The assays were performed twice and 




                             
 Naja venom                Bitis venom  
 
Figure 3. Recognition of some African snake venom components by horse 
antivenoms (first immunization). Venom components were separated on 
15% SDS-PAGE and either stained with Coomassie Blue, or transferred to 
PVDF (immobilon P membrane). Western blot analysis was performed using 
predetermined antivenom dilutions as the first antibodies and a peroxidase-
conjugated goat anti-horse-IgG as the second antibodies.  Bitis venom 
(right); B. Naja (left) venom. A) SDS-PAGE; B) Western blot (IgG from 














































Figure 4. Anti-venom antibodies titers in pooled horse sera and in corresponding F(ab´)2 
preparations. Various dilutions of the anti-venom preparations were added on 96-well pre-
coated with 1.0 µg of snake venom as indicated and results expressed either as absorbance 
at 492 nm. Data are presented as mean of triplicates. The assays were performed twice and 




different venoms obtained from several snakes in order to 
eliminate intra-specific variation discussed by Theakston 
(1996). According to conclusions reached by the 
participants of the previously-referred-to meeting to discuss 
progress in the standardization and control of anti-
venoms, organized by the Quality Assurance and Safety 
of Biologicals Unit of WHO, which was held at the 
National Institute for Biological Standards and Control, 
Potters Bar, England, 7-9 February 2001 (Theakston et 
al., 2003),  anti-venom immunotherapy mostly uses anti-
bodies that are as specific as possible in order to 
guarantee safety and efficacy. In order to meet these 
requirements, polyvalent anti-Bitis or anti-Naja anti-
venoms were developed using, as immunogens, snake 
venom from the snakes considered to be the most 
dangerous in some Mozambique African regions. Healthy 
horses were employed as anti-venom producers and 
were submitted to long immunization schedules to favor 
production of more efficient and high-affinity antibodies. 
Members of the Bitis and Naja genera are the commonest 
inflictors of snake bites and envenoming in the African 
Portuguese-speaking countries of Guine, S. Tome, 
Angola and Mozambique as described by Broadley 
(1968), Manacas (1981, 1982) and Warrell et al. (1975). 
According to unofficial registers, most victims are from 
rural areas and savanna. Bites are commonly inflicted on 
on the feet or ankles of farmers, plantation workers, 
herdsmen and hunters, who tread on snakes in the 
undergrowth or on bush paths at night (Warrell et al., 











Figure 5. Quantification of anti-venom antibodies in final F(ab´)2 preparations by ELISA. Various 
dilutions of the anti-venom preparations were added on 96-well pre-coated with 20 µg of snake 
venom as indicated and absorbance at determined at 492 nm.  The results were expressed as the 
number of U – ELISA / ml of preparations. Data are presented as mean of triplicates. The assays 




other African countries, mortality due to snake bites is by 
far underestimated (Warrell and Arnett, 1976). B. arietans 
is responsible for more fatalities than any other African 
snake. Some factors, such as its wide distribution, 
common occurrence, large size, potent venom that is 
produced in large amounts, long fangs that inject it 
deeply, their reliance on camouflage which makes these 
snakes reluctant to flee, their habit of basking by 
footpaths and sitting quietly when approached and their 
willingness to bite explain the importance of this snake in 
snake bite envenoming in the African region as discussed 
by  Spawls and Branch (1995), Mallow  et al.(2003) and 
Spaws  et al. (2004). The venom is one of the most toxic 
of any viper (Spawls and Branch, 1995). Its LD50 values 
in mice vary (0.4-2.0 mg/kg i.v., 0.9-3.7 mg/kg, i.p. 4.4- 
7.7 mg/kg, s.c. (Spawls and Branch, 1995). The average 
specimen may have enough venom to kill 4 to 5 adult 
victims (Brown, 1973). B. arietans venom is rich in various 
enzymes, mainly proteinases. Swelling and bruising may 
develop at the site of the bite within a few minutes or 
hour. Swelling spreads rapidly and sometimes involves 
the whole of the bitten limb and trunk. Regional lymphatic 
vessel and lymph node involvement is common. 
Blistering and necrosis may develop at the site of the bite. 
Haemostatic abnormalities, clinically manifested by 
persistent bleeding from the fang puncture wounds and 
other partially healed wounds, suggest coagulopathy. The 
blood clot alterations are sometimes reflected systemically 
as epistaxis, haematemesis, cutaneous ecchymoses, 









Table 1. Polyvalent Anti-Bitis and Anti-Naja F(ab´)2  preparations: Final products.   
 
F(ab’)2 ED50 Statistical Analysis* 
Anti-Naja spp. (melanoleuca and 
mossambica) 66.5 
Potency =                                 1.346337 mg/ml 
Precision factor =                             0.2257607 
Standard deviation =                   8.349235E-02 
Superior confidence limit (95%) =      80.73936 
Inferior confidence limit (95%) =         54.96681   
Anti-Bitis spp. (gabonica and nasicornis) 107.1221 
Potency =                                 4.617909 mg/ml 
Precision factor =                             0.3511864 
Standard deviation =                        0.1193328 
Superior confidence limit (95%) =      156.0412 
Inferior confidence limit (95%) =        90.06866 
Anti-Bitis arietans 1.148631 
Potency =                                 3.343111 mg/ml 
Precision factor =                                 14.2679 
Standard deviation =                        0.1439631 
Superior confidence limit (95%) =    0.4204936 
Inferior confidence limit (95%) =      0.2166872 
 







Figure 6. Western blot analysis. Samples names are 
labeled: Ten micrograms of purified F(ab´)2 and the original 
IgG(T) anti - venom previously equalized to contain each 
1.0 mg of protein/ml and elctrophoresed on 10% SDS-
PAGE. The protein bands were revealed by a monospecific 









subconjuntival, retroperitoneal, subaracnoid, intracranial 
haemorrhages (Warrell 1996). These venom effects can 
be completely and acutely reversed in response to 
specific anti-venoms, if the patients or bitten animals are 
properly treated. 
The Naja genus comprises several cobra species distri-
buted in Asia (N. naja, N. kaouthia and N. siamensis) and 
on the African continent (N. nigricolis, N. mossambica 
and N. melanoleuca). Their venoms, essentially neurotoxic, 
induce minimal local effects, usually restricted to small 
fang puncture wounds, exceptionally with tender local 
swelling, blistering and superficial necrosis (Reid, 1964; 
Viravan et al., 1986). Early systemic envenoming 
symptoms are vomiting, heaviness of the eyelids, blurred 
vision, fasciculation, paraesthesiae around the mouth, 
hyperacusis, headache, dizziness, vertigo, hypersalivation, 
congested conjunctivae and “gooseflesh”. Ptosis and 
external ophthalmoplegia appear soon after the bite, 
followed minutes or hours later by paralysis of the face, 
jaws, tongue, vocal cords, neck muscles and (bulbar) 
muscles of deglutition with pooling of secretions in the 
pharynx. The intercostals and diaphragm become 
paralyzed, leading to abdominal breathing, respiratory 
distress, with agitation, tachycardia, sweating and central 
cyanosis (Warrell, 1996).  The highest toxicity for venom, 
0.96 µg/mouse, found in our determinations of ED50 is 
compatible with previously published data of 0.9-74 
µg/mouse. With some individual variations in horses 
immunized with African snake venoms, anti-venom 
antibodies first appeared in plasmas one week after 
starting the immunization schedule, as revealed by the 
double immune diffusion method (data not shown). The 
antibody titers, subsequently determined by ELISA, 
increased until attaining a plateau. Higher antibody titers, 
observed in plasmas from horses immunized with B. 
arietans as compared with B. nasicornis and B. rhinoceros, 
were maintained along the entire immunization period. 
Such potent unexpected immunogenicity was also 
reflected both in the complete antibody molecule or in its 
F(ab´)2 fragment with a high capacity for neutralizing the 
venom-induced lethality. In contrast, horses immunized 
with N. melanoleuca and N. mossambica demonstrated 
anti-venom antibody production, although this production 
was only detectable during the initial immunization period 
and increased significantly during the second set of 
immunizations. These antibodies, as well as anti-Bitis 
antibodies are efficient at neutralizing the Naja venom 
lethality. 
A summary of the production of potent sterile batches 
of polyvalent anti-Bitis and anti-Naja anti-venoms F(ab´)2 
is indicated in the Process and Flow Diagram (Figure 1). 
As is indicated by Western blot analysis using 
monospecific goat anti-horse IgG(T) the molecular mass 
of the IgG(T) antibodies present in the polyvalent anti-
Africa snake venoms, when submitted to pepsin cleavage 





reduction in the immunoglobulin molecular mass without 
noticeable loss in their ability of neutralizing the venoms 
lethality, indicate that the IgG(T) Fc molecular portion 
were cleaved leaving intact the F(ab`)2, portion of the 
most of the antibodies. 
Quantities of 40 ml of anti-venom free of bacterial, 
lipopolysaccharides and other toxic substances were 
dispensed into sterile flasks. Flasks were labeled with total 
protein contents and the lethality neutralizing potency 
was adjusted. These anti-venoms will be submitted to 
clinical field trials under the supervision of expert medical 
doctors. 
In order to minimize the expected adverse reactions, 
upon injection into the bitten victims, the IgG immuno-
globulins were partially purified, enzymatically cleaved 
with pepsin enzyme and the resulting F(ab´)2 fragments 
were concentrated and tested for their anti-venom 
neutralizing properties. Preparations of F(ab´)2 fragments 
resulting from plasma of horses immunized with B. 
arietans (G#1) and B. nasicornis plus B. rhinoceros (G#2) 
were mixed together and labeled as Polyvalent Anti-Bitis  
Antivenom. Similarly, preparations of F(ab´)2 fragments 
resulting from the plasma of horses immunized with N. 
melanoleuca plus N. mossambica (G#3) was labeled as 
Polyvalent Anti-Naja Antivenom(nasicornis), but not 
against Naja sp. The anti-venom was effective, with 
different potency,of neutralizing the individual toxic 
activities of the venoms.  
The parameters included in Table 1 indicate that both 
polyvalent antivenoms, developed by the described 
method, posses high anti-venom antibody titers and, 
most important, exhibit sufficient lethality-neutralizing 
activity and are free of toxic substances, as well as of 
microbial contaminants and are therefore in conditions to 
be used for the immunotherapy of victims bitten by 
venomous African snakes. Theses anti-venoms will be 
submitted to clinical trials. The Polyvalent Anti-Bitis 
Antivenom, Batch IB-BT # 01/07, was recently released 
for use o treat victims bitten by snakes of the Bitis genus.   
The “Polyvalent Anti-Bitis antivenom” is capable of 
neutralizing, in vivo, the myotoxicity of three Bitis venoms 
(B. rhinoceros, B. arietans and B. nasicornis). This effect 
was evaluated by measurement of plasma  creatine 
kinase (CK) activity a well recognized parameter of 
muscle cells damage a hallmark signal of myotoxic 
damage induced by several snake venoms (Pontes et al., 
2009).  
Recent published data indicate that a polyspecific anti-
venom native IgG (T) manufactured by caprylic acid 
fractionation from the plasma of four horses that had 
immunized with a mixture of the venoms of E. ocellatus, 
B. arietans and N. nigricollis, are endowed with antivenom 
neutralizing activities (Segura, et al. 2009). The lethality, 
hemorrhagic, coagulant and necrotizing neutralizing 
activities of this IgG horse antibody were analyzed, in a 









ocellatus, E. leucogaster  and E. pyramidum leakeyi) and 
Bitis (B. arietans, B. gabonica (Nigeria), B. gabonica 
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